Navigation Links
A brush with the U.S. Regulators can cost a fortune

The Food and Drug Administration held a meeting with Boston Scientific to talk about the repairs in the quality control problems.

A similar meeting was held in 2001 with Schering-Plough // about problems with its manufacture of asthma inhalers.

But the company failed to make any amendments. This provoked the FDA to withhold approval of Clarinex, a blockbuster allergy drug.

To solve this problem Raul E. Cesan, the company's president and chief operating officer with his executive team flew to Puerto Rico for a meeting with F.D.A. inspectors and officials.

The executives said that the meeting was very tense and Mr. Cesan was known for his autocratic style. One of the executives said that after a week there were FDA inspectors crawling in all the plants.

They found more problems and the approval of the drug Clarinex was delayed by more than a year.

The company also paid a fine of about $500 million. Mr. Cesan left the company in 2001 and has since founded an investment partnership. He is also a director of The New York Times Company.

In case of Boston Scientific if F.D.A. officials detect any defiance, the company could be in trouble.

Daniel E. Troy, a Washington lawyer who is a former F.D.A. general counsel said that in times of overall management failures the company has to show some efforts to repair the quality-control problems that were detailed in the agency's warning letter.

A lot depends upon how the company takes action and necessity changes.


'"/>




Page: 1

Related medicine news :

1. Cytobrush to detect oral cancer
2. Complaint about the levy of ￡1 a week for medical care alarm service, brushed of
3. Babys First Toothbrush Should Be a Cotton Swab
4. Cancer-causing Property Of Teflon Leaves US Regulators Concerned
5. Regulators Object Drug Produced from Genetically Engineered Farm Animals
6. Australian Drug Regulators Call for Revamp On The Pharmaceutical Surveillance
7. Drug Regulators Need To Think In Long-Term, Say Charities
8. European Regulators Investigate Common Painkiller Drugs
9. Canadian Regulators allow Silicone Breast Implants in Market
10. New Study Challenges How Regulators Determine Risk
11. Researchers Urge Regulators to Rethink Strategies for Soot Emission
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: brush with the Regulators can cost fortune

(Date:12/1/2008)... EXTON, Pa., Dec. 1 Vir...unced that the company submitted a supplemental,B...od and Drug Administration,(FDA) for Cinryze(TM) ...cks of,hereditary angioedema (HAE). , The ... data from a pivotal,Phase 3 acute treatment stud...
(Date:12/1/2008)... Alcohol, nicotine use, personality illnesses com...althDay News) -- Psychiatric disorders are common ...eek treatment, a new report shows. , To reach t...ore than 5,000 respondents, aged 19 to 25, who too...ohol and Related Conditions. , The study found ...
(Date:12/1/2008)... , A new analysis of the National Cancer Institut...in five older women experience delayed or incomple... surgery, and that this suboptimal care can lead t...eill Cornell Medical College and colleagues found ...early 8,000 breast cancer registry patients aged 6...
(Date:12/1/2008)... WASHINGTON, Dec. 1 /PRNewswire-USNewswire/ -- ...e release of a model state legislative resolution ...). AUL urges state legislatures to adopt the reso...ssions. , , Dr. Charmaine Yoest, AUL Presid...ice Act, endangers women,s health. It protects an...
Breaking Medicine News(10 mins):Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5Health News:Few Young Adults Seek Treatment for Psych Disorders 2Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:Americans United for Life Urges State Legislatures to Oppose Federal Power Grab: Provides Model Resolution Denouncing Freedom of Choice Act (FOCA) 2
...k we had carried a story about Wal-mart’s foray in... a pilot project which involved the lease of medic... 76 clinics actively functioning at the Wal mart s...uring the meeting of the 4th Annual World Health C...
...nd busier an NHS hospital is, the higher the MRSA ...versity Business School has revealed. The impact...MRSA infections in NHS hospitals study looked at h... imposed by hospital insurers — and the premium di...
...st vaccination of sixth-grader girls to prevent ce...-Texas Governor Rick Perry. //The move sees that T...ixth-grade girls to be vaccinated against a sexual...al cancer. Yesterday, the Texas House gave the go...
...bility and resources for public health and tacklin...cils rather than with the NHS, argues an expert in...m University says that partnerships between local ...d then become a true meeting of the two sides of h...
Other Medicine News:Health News:Better Risk Management Could Cut MRSA Infection Rates 2Health News:Local Councils Should Be Responsible for Tackling Health Inequalities 2
(Date:12/1/2008)...uled for Tuesday, December 9 at 11:00 am ET to Dis...OUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-F...: SNSS ), a biopharmaceutical company focused on...logy therapeutics, today announced new data from i...(AML) will be presented during the 50th American S...
(Date:11/28/2008)...ovember 28 German biotech company,...ialized HIV monitoring and,AIDS patient follow-up.... In,the year 2008, 2.5 million patient tests hav...ghly affordable "CyFlow" system, supporting alread.... Due to introduction of the,Partec innovation, t...
(Date:11/26/2008)...bjects , , FRANKLIN, Mass., Nov. 26 /PRNews...Board: PLCSF) announced today that it has received...tration (FDA) for its U.S. pivotal trial to study ...em(TM) and associated therapy in the prevention o...he FDA also approved PLC,s request to expand their...
(Date:11/25/2008)...if., Nov. 25 Poniard,Ph...ceutical company focused on,innovative oncology t...g,strategic alternatives for its preclinical rese...cus its resources on the clinical development of p...port the initial commercialization of,picoplatin ...
Breaking Medicine Technology:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Liver Transplant Patients at Higher Cancer Risk 27261 1Liver Transplant Patients at Higher Cancer Risk 27261 2PURE Bioscience to Announce Fourth Quarter and Fiscal 2008 Results 8212 1PURE Bioscience to Announce Fourth Quarter and Fiscal 2008 Results 8212 2Hologic Inc To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday November 11 2008 27255 1Hologic Inc To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday November 11 2008 27255 2Children 26apos 3Bs National Experts Presenting at American Academy of Pediatrics Conference 27252 1Children 26apos 3Bs National Experts Presenting at American Academy of Pediatrics Conference 27252 2
...ournal of Clinical Oncology -, NEW YORK, July 06, ...e II study - which will be published in the August...y (JCO) and are now,available as an Early Release ...o.org/">www.jco.org - demonstrate that,ixabepilon...compound, has activity in patients with metastatic...
...5, an Investigational NNRTI,from Tibotec, YARDLEY,...ongoing Phase 3 studies (DUET-1 and DUET-2) showed...mented non-nucleoside reverse,transcriptase inhibi... reached an undetectable viral load (defined as ac...A copies/mL) with,TMC125 (etravirine), Tibotec,s i...
Other Medicine Technology:Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 2Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 3Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 4TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4
11.5 mm curved hook. Flat serrated handle with polished finish. Overall length: 5.9 inches.
Designed for manipulating one piece lenses. The "Y: hook is excellent for capturing haptics and centering the lens. Straight shaft with "Y" shaped tip. Round knurled handle with dull finish. Overall
0.2 mm Sinskey hook with shaft angled 45 degrees, 10 mm from tip to bend. Flat smooth handle with polished finish. Overall length: 4.6 inches.
0.3 mm hook angled 45 degrees, 9 mm from tip to bend. Flat smooth handle with polished finish. Overall length: 4.6 inches.
Medicine Products: